Show Summary Details
Page of

Glioblastoma multiforme 

Glioblastoma multiforme
Chapter:
Glioblastoma multiforme
Author(s):

Mohammed Awad

DOI:
10.1093/med/9780199656400.003.0002
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 12 April 2021

Glioblastoma multiforme (GBM) is the most common form of malignant primary brain tumour. In the UK the incidence is approximately 2-3 cases per 100,000 people per year. It accounts for approximately 20% of all primary intracranial tumours. GBM is derived from glial cells, and is thought to arise either de novo as primary GBM, or secondary to malignant progression from a low-grade astrocytoma. This chapter discusses how to recognise and treat glioblastoma multiforme. Clearly the prognosis for patients with malignant glioma remains poor with median survival for those with GBM in the region of 12-14 months. This has only changed marginally over the last few decades with the use of systemic chemotherapy alongside surgical resection and radiotherapy. There are outliers who do better or worse than the median and 3 year survival percentages do seem to be increasing with current treatment regimes. There is currently a resurgence of interest in the immunology and metabolism of these tumours in the search for magic bullets.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.